Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan

Seiya Sato, Yoshiaki Nakamura, Eiji Oki, Takayuki Yoshino

研究成果: ジャーナルへの寄稿総説査読

1 被引用数 (Scopus)

抄録

The body of evidence supporting the utility of the detection of molecular residual disease (MRD) in resected colorectal cancer (CRC) using circulating tumor DNA (ctDNA) analysis is rapidly growing. Furthermore, this evidence provides the rationale for escalation and de-escalation adjuvant chemotherapy (ACT) strategies using ctDNA MRD analysis. This has led to various randomized clinical trials, and CIRCULATE-Japan is one of the largest of these trial platforms. In this review, we provide an overview of the potential utility of ctDNA-based MRD detection for escalation and de-escalation ACT approaches. Furthermore, we highlight the feasibility using ctDNA clearance as a surrogate endpoint for ACT trials in patients with resected CRC, based on findings of the CIRCULATE-Japan project.

本文言語英語
ページ(範囲)53-58
ページ数6
ジャーナルClinical Colorectal Cancer
22
1
DOI
出版ステータス出版済み - 3月 2023

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 消化器病学

フィンガープリント

「Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル